<DOC>
	<DOCNO>NCT01676597</DOCNO>
	<brief_summary>- The study prospective open label double blind randomize control study . - The study conduct patient admit Department Hepatology 2012 2014 Institute Liver Biliary Sciences , New Delhi - Patients diagnosed clinical subclinical hepatopulmonary syndrome start oral pentoxifylline therapy 400 mg thrice daily 12 week . - Patients respond therapy give divide 2 arm one arm receiving additional Tab Rifaximin 400 mg thrice daily placebo 12 week .</brief_summary>
	<brief_title>Efficacy Pentoxifylline Rifaximin Combination Pentoxifylline Refractory Clinical Subclinical Hepatopulmonary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatopulmonary Syndrome</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>1 . Evidence portal hypertension ( esophagogastric varix portal hypertensive gastropathy identify esophagogastroduodenoscopy , and/or varix see computerized tomography scan ultrasound , and/or splenomegaly explanation , and/or ascites explanation ) 2 . Intrapulmonary vascular dilatation ( IPVDs ) diagnose contrast echocardiogram ( CE ) 3 . AaDO2 &gt; 15 mm Hg standing room air arterial blood gas ( ABG ) 4 . Ability willingness give inform consent Age &lt; 18 &gt; 64 Intrinsic significant cardiopulmonary disease Inability perform pulmonary function test Moderate severe Pulmonary hypertension Advanced hepatic encephalopathy Inadequate echocardiographic window allow accurate transthoracic contrast echocardiography Antibiotic use within last one month Listed liver transplant next 4 week Current use exogenous nitrate Active bacterial infection Known malignancy Known intolerance Pentoxifylline rifaximin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>